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CASE REPORT
CMV AND HSV-2 MYELORADICULITIS IN AN HIV INFECTED PATIENT
Adriana PINTO, Edwiges SANTOS, Danusa F. CORREA, Rodrigo ESCADA, Carla de Mello VORSATZ, 
Sandra Wagner CARDOSO & Marco A. LIMA
SUMMARY
While CMV myeloradiculitis is a known complication in AIDS patients with severe immunosuppression, HSV-2 necrotizing 
myeloradiculitis is rare and often associated with disabling a fatal outcome. We hereby describe a 46 year-old HIV infected patient 
with profound and sustained immunosuppression who presented with an acute ascending paraparesis and urinary retention. Lumbar 
spine MRI showed contrast enhancement at the conus medullaris and cauda equine, and both CMV and HSV-2 CSF PCR were positive. 
Despite treatment, the patient died 20 days later. We review the main diagnostic and therapeutic aspects of herpes virus associated 
myeloradiculitis and discuss the approach in similar cases. 
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INTRODUCTION
Currently, there are more than 33 million people living with HIV 
around the world. The introduction of highly active antiretroviral therapy 
(HAART) brought an improvement in the survival rate and a decrease in 
the incidence of opportunistic infections. Concerning the opportunistic 
infections of the central nervous system (CNS), recent studies have shown 
a decrease in the incidence of progressive multifocal leukoencephalopathy 
(PML), CMV encephalitis and myelitis as well as other herpesviruses-
associated diseases19.
Nevertheless, there is a proportion of HIV infected patients under 
treatment that become resistant to any HAART regimen during the course 
of the disease13. In such individuals, the CD4+ T cell count is persistently 
low and opportunistic infections are common in this scenario. In 
particular, disseminated cytomegalovirus (CMV) infection, disseminated 
Mycobacterium avium complex (MAC) and Epstein Barr virus associated 
primary central nervous system lymphoma frequently occur when CD4+ 
T cell count is under 50 mm3 (5). Furthermore, concomitant infections 
may occur in patients with advanced immunosuppression, increasing 
morbidity and mortality. 
In this study, we sought to describe a long-term AIDS patient with 
HAART failure, who developed a myeloradiculitis due to concurrent 
HSV-2 and CMV infections, and review the diagnostic and therapeutic 
approaches in similar cases. 
CASE REPORT
A 46 year-old male HIV infected patient presented with a five-day 
history of progressive bilateral, asymmetric ascendant weakness in 
the lower limbs, associated with hypoesthesia, imbalance and urinary 
retention. His physical examination showed an asymmetric flaccid 
paraparesis, abolished deep tendon reflexes in the lower extremities 
and diminished in the upper extremities. There was sensory loss in the 
feet, but the patient had already had a previous diagnosis of HIV-related 
sensory neuropathy. 
His previous history revealed a diagnosis of HIV infection in 1993. 
His most recent HIV viral load was 23,100 copies/mL and the CD4+ T 
lymphocyte count was 2 cells/mm3. His T CD4+ cell count had been under 
20 cells/mm3 in the previous three years despite several antiretroviral 
regimens. At the time he was taking lamivudine, raltegravir, ritonavir, 
etravirine and darunavir. Ten months before admission, a diagnosis of 
CMV retinitis was made. He received initially 21 days of IV ganciclovir 
5 mg/kg every 12h as induction treatment. However, he could tolerate 
IV maintenance treatment due to bone marrow suppression despite of 
the daily filgrastrim use, and was switched to intravitreal ganciclovir 
2.5 mg weekly one month before admission. There was no clinical 
evidence of systemic CMV infection, but no blood CMV PCR or CMV 
pp65 antigenemia were performed. Two weeks before the development 
of neurological symptoms, he presented with a pruriginous and painful 
anal lesion that was diagnosed as secondary to HSV infection. 
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 A lumbar spine magnetic resonance (MR) demonstrated contrast 
enhancement at the conus medullaris and cauda equina (Fig. 1). 
The cerebrospinal fluid (CSF) analysis disclosed 22 cells/mm3 with 
mononuclear predominance, glucose: 42 mg/dL, protein: 225 mg/dL. 
Stains and cultures for bacteria, mycobacteria and fungi were negative. 
Pending results of herpes viruses CSF PCR, he was started on intravenous 
ganciclovir. Both CSF HSV-2 and CMV PCR were positive, but, again, 
the therapy had to be suspended after 16 days because of severe bone 
marrow suppression. The patient developed septic shock associated with 
multidrug-resistant Pseudomonas aeruginosa infection and died 20 days 
after hospitalization.
DISCUSSION
Ascending myelitis syndrome is associated with infection by different 
agents such as CMV, HSV-1, HSV-2, Varicella zoster, Treponema 
pallidum, Toxoplasma gondii and Schistosoma mansoni4. In particular, 
Herpes viruses are neuropathic viruses, which can cause myelitis/
polyradiculopathy, especially in immunosuppressed individuals. In 
AIDS patients, most cases are related to CMV infection, mainly at 
advanced stages, when T CD4+ cell count < 50 cell/mm3 (12). CMV 
myelitis is often associated with CMV infection in other organs11. In 
our patient, CMV retinintis had been diagnosed previously, but we were 
not able to show systemic CMV infection at the onset of neurological 
disease, nor determine CMV viral load since blood CMV PCR was not 
available at our institution. The clinical picture is of a painful rapidly 
ascending paraparesis with urinary retention. CSF analysis usually 
shows a neutrophilic pleocytosis with hypoglycorrhachia and elevated 
protein levels, although a normal cell count can be observed, which 
can make diagnosis difficult. CMV CSF PCR is highly sensitive and 
specific for diagnosis and higher viral loads are observed in patients 
with CMV myelitis than in encephalitis21. Combination treatment with 
ganciclovir and foscarnet is recommended as the optimal approach, but 
evidence is scarce. ANDUZE-FARIS et al. evaluated 31 individuals 
with CMV encephalitis or myelitis and observed improvement or 
stabilization in 74% of the patients treated with this regimen1. Failure 
to respond to ganciclovir monotherapy is common. Possible factors are 
the poor penetration of the drug into the CNS, development of resistant 
ganciclovir strains or irreversible neurological damage1,20. Genotypical 
and phenotypical susceptibility testing should be performed when clinical 
improvement is not observed, but these tests are not available in most 
centers in developing countries. 
HSV-2 is an important cause of encephalitis in neonates. Additionally, 
after primary infection, it establishes latent infection in sacral ganglia and 
may be responsible for a recurrent lymphocytic meningitis (Mollaret`s 
meningitis) at the time of recurrences22. In immunocompromised 
individuals, HSV-2 can rarely cause encephalitis or myelitis3. Any 
combination of flaccid paraparesis, loss of sensation, urinary retention, 
constipation and erectile dysfunction can be observed9. As observed in 
our patient, a previous or concurrent HSV-2 rash in the anogenital area 
can be seen in some patients. CSF HSV-2 PCR has replaced biopsy as 
gold standard with a sensitivity and specificity higher than 95%. However, 
PCR results should be interpreted in relation of time of CSF collection. 
Negative results can be observed in the first 72 hours, or in patients already 
being treated with acyclovir. In such cases, a retrospective diagnosis of 
CNS HSV-2 infection can be carried out in 80% of patients by a fourfold 
increase in the titers of HSV antibodies after one month6. Treatment with 
IV acyclovir for 10-14 days results in improvement in most patients, but 
severe myelitic deficits may persist despite therapy16. Additionally, there 
are reports of HIV infected patients with HSV-2 myeloradiculitis who 
had a favorable outcome after being treated with this drug2,7. However, 
we decided not to add it since ganciclovir is also efficacious against both 
viruses15 and in order to avoid additional side effects. Foscarnet would 
be an interesting option since it is efficacious against both CMV and 
HSV-2 and has a good CSF penetration18. Nevertheless, this drug is not 
readily available in our country.
Neuropathological findings in herpes virus associated necrotizing 
myeloradiculitis include extensive necrotic and hemorrhagic changes 
associated with necrotizing vasculitis and perivascular lymphocytic 
infiltration involving both gray and white matter as well as spinal roots10,14. 
Infection of the CNS by two or more viruses is a well-recognized 
event24, but myelitis due to concurrent HSV-2 and CMV infection is 
extremely rare and probably related to severe immune system impairment, 
as observed in our patient. In this case, there was evidence of HSV 
cutaneous reactivation concurrent to the development of the neurological 
picture. In addition, systemic ganciclovir maintenance treatment had 
been stopped one month before admission, which predisposed him to a 
systemic CMV reactivation. In a setting of persistent low CD4+ T count 
and impaired cellular response, both viruses were able to invade the spinal 
cord. Since either CMV or HSV-2 can infect multiple cell types (neurons, 
astrocytes, oligodendrocytes and microglia) in the CNS3,12 we can speculate 
on a possible synergistic effect of this concurrent infection in producing 
spinal cord lesion. To corroborate this hypothesis, we were able to find only 
Fig. 1 - Lumbar spine T1-weighted MRI sequence showing contrast enhancement of the 
conus medullaris and cauda equina. 
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three previous reports8,17,23 in HIV patients. All these patients had profound 
immunosuppression, and the prognosis was grim in the two patients it was 
available (death in one and minimal recovery in the other). 
In conclusion, neurological deficits in immunosuppressed individuals 
can be secondary to more than one infectious agent. A careful review of 
the medical history coupled to a rational use of imaging and CSF analysis 
can disclose multiple infections in the CNS, allowing the proper treatment 
and reduction of morbidity and mortality. 
RESUMO
Mieloradiculite por CMV e HSV2 em paciente infectado pelo HIV
Enquanto a mieloradiculite pelo CMV é complicação conhecida 
em pacientes com SIDA e imunossupressão grave, a mieloradiculite 
necrosante por HSV-2 é rara e muitas vezes associada a sequelas ou 
desfecho fatal.  Descrevemos um paciente de 46 anos de idade, infectado 
pelo HIV com imunossupressão profunda e sustentada que apresentou 
paraparesia aguda ascendente e retenção urinária.  A RM de coluna 
lombar mostrou o realce de contraste no cone medular e cauda equina 
e ambos PCR para CMV e HSV-2 no LCR foram positivos.  Apesar do 
tratamento, o paciente morreu 20 dias depois.  Revisamos os principais 
aspectos diagnósticos e terapêuticos da mieloradiculite associada aos 
herpesvírus e discutimos a abordagem em casos semelhantes. 
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